What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Pharmacology
- Enzyme
David Back mostly deals with Pharmacology, Pharmacokinetics, Internal medicine, Ritonavir and Endocrinology.
His specific area of interest is Pharmacology, where David Back studies Drug interaction.
His Pharmacokinetics research is multidisciplinary, relying on both Oral administration, CYP3A4, Chemotherapy and Zidovudine.
David Back combines subjects such as Antibiotics, Rifampicin, Gastroenterology, Anticonvulsant and Single-nucleotide polymorphism with his study of Internal medicine.
His studies in Ritonavir integrate themes in fields like Protease inhibitor, Lopinavir, HIV Protease Inhibitor, Saquinavir and Indinavir.
His biological study deals with issues like Bioavailability, which deal with fields such as Volume of distribution.
His most cited work include:
- Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. (618 citations)
- Darunavir: pharmacokinetics and drug interactions. (303 citations)
- Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes (293 citations)
What are the main themes of his work throughout his whole career to date?
David Back mainly focuses on Pharmacology, Pharmacokinetics, Internal medicine, Endocrinology and Ritonavir.
David Back works mostly in the field of Pharmacology, limiting it down to topics relating to Zidovudine and, in certain cases, Lamivudine, as a part of the same area of interest.
His work deals with themes such as Oral administration, Area under the curve, Reverse-transcriptase inhibitor and Virology, which intersect with Pharmacokinetics.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Bioavailability.
His studies deal with areas such as Microsome and Norethisterone as well as Endocrinology.
His Ritonavir research also works with subjects such as
- Saquinavir which is related to area like Indinavir and Nelfinavir,
- Lopinavir together with Lopinavir/ritonavir.
He most often published in these fields:
- Pharmacology (53.09%)
- Pharmacokinetics (36.61%)
- Internal medicine (31.85%)
What were the highlights of his more recent work (between 2011-2021)?
- Pharmacology (53.09%)
- Pharmacokinetics (36.61%)
- Drug (12.84%)
In recent papers he was focusing on the following fields of study:
David Back spends much of his time researching Pharmacology, Pharmacokinetics, Drug, Efavirenz and Ritonavir.
His Pharmacology research focuses on Raltegravir and how it connects with Raltegravir Potassium.
Pharmacokinetics is a subfield of Internal medicine that David Back investigates.
In Drug, David Back works on issues like Intensive care medicine, which are connected to Disease and Coronavirus disease 2019.
His work is dedicated to discovering how Efavirenz, Nevirapine are connected with Obstetrics and other disciplines.
As a part of the same scientific study, he usually deals with the Ritonavir, concentrating on Lopinavir and frequently concerns with Lopinavir/ritonavir.
Between 2011 and 2021, his most popular works were:
- Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (101 citations)
- Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine (75 citations)
- A Compartmental Pharmacokinetic Evaluation of Long‐Acting Rilpivirine in HIV‐Negative Volunteers for Pre‐Exposure Prophylaxis (75 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Enzyme
- Pharmacology
Pharmacology, Pharmacokinetics, Efavirenz, Nevirapine and Lopinavir are his primary areas of study.
He combines subjects such as Internal medicine, Atazanavir and Ritonavir with his study of Pharmacology.
His Pharmacokinetics research incorporates elements of Pre-exposure prophylaxis, Confidence interval, Dosing and Emtricitabine.
His Efavirenz study combines topics from a wide range of disciplines, such as Half-life, Virology, Pharmacogenetics, Cmax and Breast milk.
His Nevirapine research focuses on Rilpivirine and how it relates to IC50.
He interconnects Organic anion transporter 1, SLCO1B1, Protease and Genotype in the investigation of issues within Lopinavir.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
